📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. (2015)

First Author: Williams B

Attributed to: The Evaluation of blood pressure treatment stratified according to Central Aortic Systolic Pressure (CASP) in Young Hypertensive Patients - The TREAT CASP study funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(15)00257-3

PubMed Identifier: 26414968

Publication URI: http://europepmc.org/abstract/MED/26414968

Type: Journal Article/Review

Volume: 386

Parent Publication: Lancet (London, England)

Issue: 10008

ISSN: 0140-6736